Irinotecan Kabi (Irinotecan Hydrochloride Trihydrate)

Irinotecan Kabi is used in colorectal cancer treatment regimens that target tumor cell proliferation.

• Metastatic colorectal cancer: improves overall survival when combined with fluoropyrimidine‑based chemotherapy.
• Refractory colorectal cancer: provides clinical benefit in patients whose disease has progressed after first‑line therapy.
• Advanced colorectal cancer (first‑line): forms part of the standard FOLFIRI regimen to reduce tumor burden.

• Irinotecan Hydrochloride Trihydrate is converted intracellularly to SN‑38, a potent inhibitor of topoisomerase I. By stabilizing the DNA‑topoisomerase I complex, it prevents religation of single‑strand DNA breaks during replication, leading to accumulation of DNA damage and ultimately tumor cell apoptosis.

Irinotecan Kabi may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects

• Nausea and vomiting
• Diarrhea, which can be severe
• Neutropenia and leukopenia
• Alopecia (hair loss)
• Fatigue and weakness
• Decreased appetite

Serious or Rare Side Effects

• Febrile neutropenia or severe bone‑marrow suppression
• Life‑threatening colitis or severe diarrhea
• Hepatic toxicity with elevated transaminases
• Hypersensitivity reactions including anaphylaxis
• Pulmonary toxicity such as interstitial pneumonitis
• Severe electrolyte disturbances

Before initiating therapy, clinicians should assess patient‑specific factors and monitor for toxicity.

• Dose adjustment: required in patients with hepatic impairment.
• Baseline labs: obtain complete blood count and liver function tests prior to each cycle.
• Diarrhea management: initiate antidiarrheal prophylaxis and monitor fluid balance.
• Myelosuppression: monitor neutrophil counts and consider growth‑factor support if needed.
• Pregnancy and lactation: avoid use unless benefits clearly outweigh potential risks.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Irinotecan may interact with other medicines that affect its metabolism or increase toxicity.

Major Interactions (Avoid)

• Strong CYP3A4 inducers (e.g., rifampin) markedly reduce irinotecan exposure.
• UGT1A1 inhibitors (e.g., atazanavir) can increase SN‑38 levels and raise risk of severe neutropenia.
• Concurrent myelosuppressive agents may cause profound bone‑marrow suppression.

Moderate Interactions (Monitor Closely)

• Anticholinergic drugs may exacerbate irinotecan‑induced diarrhea.
• Anticoagulants can increase bleeding risk when hepatic function is compromised.
• Moderate CYP3A4 inhibitors (e.g., ketoconazole) may raise plasma concentrations, requiring dose adjustment.